Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 620)
Posted On: 06/15/2021 2:03:16 PM
Post# of 155790
Posted By: CTMedic
Critical trial

RESEARCH PROJECT DATA
Public Title: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Leronlimab in combination with standard treatment for critically ill patients with 2019 coronavirus pneumonia (COVID19) requiring mechanical ventilation or extracorporeal membrane oxygenation.
PI: REMO NETHERLANDS OF MENDONCA FURTADO
Public Contact: STOLEN MENDONCA NETHERLANDS REMO
Health conditions or problems studied: COVID19
Pneumonia
ICD Descriptors - General: COVID-19, virus identified
ICD Descriptors - Specific: COVID-19, virus identified
ICD - Intervention Descriptors: COVID-19, virus identified
CEP/CONEP Ethics Approval Date: 06/15/2021


DATA FROM THE PROPOSING INSTITUTION

DATA OF THE RESEARCH ETHICS COMMITTEE
Responsible Ethics Committee: 71 - Hospital Israelita Albert Einstein-SP
Address: Av. Albert Einstein 627 - 2ss
Phone: (11)2151-3729
E-mail: cep@einstein.br

RESEARCH PROJECT PARTICIPANT CENTRE(S)

RESEARCH PROJECT CO-PARTICIPANT CENTER(S)

https://plataformabrasil.saude.gov.br/login.jsf













(12)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site